Literature DB >> 9521055

Quantitative control of MHC class II expression by the transactivator CIITA.

L A Otten1, V Steimle, S Bontron, B Mach.   

Abstract

Activation of T lymphocytes is quantitatively controlled by the level of expression of MHC class II molecules. Both constitutive and inducible expression of MHC class II genes is regulated by the transactivator CIITA, which is itself tightly regulated. Since the level of MHC class II molecules expressed is a functionally essential parameter, it was of interest to explore whether MHC class II expression is quantitatively controlled by the level of the transactivator. This report shows that in a variety of experimental conditions one does indeed observe, in both mouse and man, a quantitative control of MHC class II expression by the level of CIITA. This relationship between the regulator gene, which behaves as a rate-limiting factor, and its target genes clarifies our understanding of the quantitative modulation of MHC class II expression, and thus of T lymphocyte activation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9521055     DOI: 10.1002/(SICI)1521-4141(199802)28:02<473::AID-IMMU473>3.0.CO;2-E

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  22 in total

1.  CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex.

Authors:  K Masternak; A Muhlethaler-Mottet; J Villard; M Zufferey; V Steimle; W Reith
Journal:  Genes Dev       Date:  2000-05-01       Impact factor: 11.361

2.  IFN-gamma-dependent transcription of MHC class II IA is impaired in macrophages from aged mice.

Authors:  C Herrero; L Marqués; J Lloberas; A Celada
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

Review 3.  Class II transactivator: mastering the art of major histocompatibility complex expression.

Authors:  J A Harton; J P Ting
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

4.  Downregulation of CIITA function by protein kinase a (PKA)-mediated phosphorylation: mechanism of prostaglandin E, cyclic AMP, and PKA inhibition of class II major histocompatibility complex expression in monocytic lines.

Authors:  G Li; J A Harton; X Zhu; J P Ting
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

5.  CIITA leucine-rich repeats control nuclear localization, in vivo recruitment to the major histocompatibility complex (MHC) class II enhanceosome, and MHC class II gene transactivation.

Authors:  S B Hake; K Masternak; C Kammerbauer; C Janzen; W Reith; V Steimle
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

Review 6.  Regulation and function of class II major histocompatibility complex, CD40, and B7 expression in macrophages and microglia: Implications in neurological diseases.

Authors:  George M O'Keefe; Vince T Nguyen; Etty N Benveniste
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

Review 7.  Novel mechanisms of class II major histocompatibility complex gene regulation.

Authors:  Michael Radosevich; Santa Jeremy Ono
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

8.  The antagonism of interferon-gamma (IFN-gamma) by heparin: examination of the blockade of class II MHC antigen and heat shock protein-70 expression.

Authors:  S J Fritchley; J A Kirby; S Ali
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

9.  Relationship between polymorphism of class II transactivator gene promoters and chronic hepatitis B.

Authors:  Ying-Ren Zhao; Ling Gong; Ying-Li He; Fang Liu; Chang Lu
Journal:  World J Gastroenterol       Date:  2005-02-14       Impact factor: 5.742

10.  Altered T cell development in human thymoma is related to impairment of MHC class II transactivator expression induced by interferon-gamma (IFN-gamma).

Authors:  Y Kadota; M Okumura; S Miyoshi; S Kitagawa-Sakakida; M Inoue; H Shiono; Y Maeda; T Kinoshita; R Shirakura; H Matsuda
Journal:  Clin Exp Immunol       Date:  2000-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.